EPO may not improve cycling performance at all, according to new scientific research. The banned drug increases the number of oxygen-carrying cells in the blood but a new study has raised doubts that it actually helps cyclists.
Forty-eight well-trained amateur Dutch and Belgian riders volunteered to be given EPO or a placebo for the eight week study.
"They were all riders of a good standard and exceeded our specified power/weight threshold," said Adam Cohen, chief executive of the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, which ran the study in June 2016, but which has only just been published in the Lancet Haematology journal.
"They also had to resign their membership of their national associations so they didn't infringe the sport's anti-doping rules."
Half of the cyclists were injected with the drug and half with a placebo. None of them knew what they were receiving and neither did the scientists leading the research.
"It's the protocol used in pharmacology because it is rigorous. We hadn't found any previous research into EPO of such rigour," said Cohen.
Every week each rider attended the lab to complete endurance tests, including VO2max, and to give blood samples. These were locked away so nobody could use them to identify who had the EPO in their veins until the whole experiment was over.
Is VO2 max really that important?
In the shorter, high-intensity tests, those who had been given EPO performed better, but there was no difference between then when they carried out a longer 45 minute test indoors.
After eight weeks they went for a 110km ride in June, which ended on the cold and windy summit of Mont Ventoux. The results were shocking, with those who had been given EPO climbing the mountain on average 17 seconds slower than those who had been given the placebo.
"They couldn't feel the effect and we couldn't measure it either," Jules Heuberger, who led the study, told Associated Press.
During the experiment, cyclists were questioned and none ever reported feelings of unusually enhanced power or endurance. So perhaps the effect of EPO is all in the mind?
This is the first time such detailed research has been done because it is expensive. "We are a foundation and we have financed it ourselves simply because we want to know. It has cost us about €500,000," said Cohen.
"That's the price of a mass-spectrometer in the anti-doping lab at Rio."
The World Anti-Doping Agency's science director Oliver Rabin said that he doubted the study would change the organisation's approach, but would certainly read it with interest.
"We would need much more than this," Rabin said. "The scientific community will receive this with a lot of scepticism."
This article was originally published on July 15, 2016 after the initial experiment was carried out. It was updated on June 30, 2017 after the study was published.
Max Glaskin is an award-winning freelance journalist who tweets about cycling and science as @CyclingScience1.
He is author of Cycling Science (published by Frances Lincoln UK, Chicago University Press USA, and seven other languages).
Demi Vollering wins the Women’s Tour GC as Balsamo takes her first win as world champion
Stage three time trial the key to Vollering's first top tier stage race victory
By Owen Rogers •
Patrick Lefevere reveals Brit Ethan Vernon is signing for Deceuninck - Quick-Step
The Belgian boss says the young rider will join up with the team next week
By Jonny Long •
Expert opinion: What about an athlete's right to privacy?
Paul Dimeo looks at another side of the anti-doping fight, the right to privacy for athletes
By Jack Elton-Walters •